Drugs / Ademetionine
Ademetionine
also known as
S-Adenosyl-L-Methionine · SAMe · Adenosylmethionine · Heptral · MSI-195 · S-adenosylmethionine · transmetil · Ximeixin
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04623034 | Apr → Jun 2013 | major depressive disorder | MSI Methylation Sciences, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07495995 | Apr 2026 → Dec 2030 expected | metabolic dysfunction-associated steatotic liver disease | Cedars-Sinai Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01912196 | Oct 2013 → Sep 2015 | major depressive disorder | MSI Methylation Sciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01140646 | Oct 2010 → Nov 2012 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00310336 | Aug 2006 → Aug 2009 | hepatitis C virus infection | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02200029 | Jun 2014 → Feb 2015 | intrahepatic cholestasis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01754714 | Dec 2012 → Sep 2014 | NAFLD1 | Abbott | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05598580 | Nov 2022 → May 2024 | HIV infectious disease | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05363020 | Aug 2022 → Apr 2025 | osteoarthritis, hand | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01998620 | Nov 2013 → May 2015 | cholestasis, chronic hepatitis B virus infection | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT00762268 | Sep 2008 → Sep 2011 | bipolar depression | Mclean Hospital | Completed | Missed primary |
| — | NCT00101452 | Apr 2005 → Jun 2010 | major depressive disorder | Maurizio Fava, MD | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1/2 | NCT02651350 Background | Dec 2015 → Jul 2019 | drug-induced liver injury | Beijing 302 Hospital | Completed | Met primary |
| Phase 2 | NCT07367724 Comparator | Jan 2026 → Dec 2027 expected | hypertrophic cardiomyopathy | China National Center for Cardiovascular Diseases | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00722124 Comparator | Sep 2008 → Dec 2009 | nicotine dependence | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04906083 Background | Feb 2021 → Dec 2022 | cirrhosis of liver, liver failure, thrombocytopenia | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02331745 Background | Oct 2013 → Apr 2016 | alcoholic liver disease, hepatitis B virus infection, liver failure | Beijing 302 Hospital | Unknown | No outcome recorded |
| — | NCT06922669 Background | Jun 2025 → Mar 2027 expected | drug-induced liver injury | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| — | NCT07068191 Comparator | Jun → Jul 2025 overdue | NAFLD1, alcoholic fatty liver disease | Phenomen Pharma | Recruiting | No outcome recorded |
| — | NCT01344174 Background | May → Aug 2011 | hepatitis B virus infection, liver failure | Third Military Medical University | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ademetionine | “Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission.” NCT02331745 ↗7“including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA)” NCT02651350 ↗ |
| Known as | Adenosylmethionine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05598580 ↗ |
| Known as | Heptral | “A research study of an approved drug called Heptral®, ademetionine, to treat adults with intrahepatic cholestasis” NCT02200029 ↗ |
| Known as | MSI-195 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01912196 ↗ |
| Known as | S-Adenosyl-L-Methionine | “Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)” NCT01912196 ↗8“S-adenosyl-L- methionine (500 mg, intravenously, 2/d);” NCT01344174 ↗ “1000 mg SAMe (S-adenosyl-L-methionine)” NCT01754714 ↗ |
| Known as | S-adenosylmethionine | “An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder.” PMID 30368163 ↗ Oct 2018 |
| Known as | SAMe | “S-adenosyl-L-methionine (SAMe) and betaine potentiate IFNα signaling in cultured cells that express hepatitis C virus (HCV) proteins, and enhance the inhibitory effect of IFNα...” PMID 21079746 ↗ Nov 20106“Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)” NCT01912196 ↗ “Oral S-adenosyl-L-methionine (SAMe) administered at 1,200 mg/day in two divided doses for 12 months.” NCT07495995 ↗ “Phase II Evaluation of S-Adenosyl-L-Methionine (SAMe) for the Treatment of Hot Flashes” NCT01140646 ↗ “Drug: S-Adenosyl-L-Methionine (Sam-E)” NCT05363020 ↗ |
| Known as | transmetil | “Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.” NCT04906083 ↗ |
| Known as | Ximeixin | “Its brand name is Ximeixin in China.” NCT07367724 ↗ |
| Route | Oral | “Subjects will receive oral SAMe for only 3 days per week” NCT00762268 ↗ |